With an annual increase of 100000 new patients, China has become the "largest country of Parkinson's disease". How has the drug market performed in recent years?

According to the statistics of the world Parkinson disease association, the incidence rate of Parkinson disease is 1.7% among people over 65 years old, and the incidence rate is 70 3-5% At present, there are 5.7 million Parkinson's disease patients in the world, and the number of patients in China is about 2.6 million, ranking first in the world, and the number of new patients increases by 100000 every year " According to the CMH monitoring data of Zhongkang, in recent years, the market scale of Parkinson's disease drugs in China has continued to grow, reaching 2.3 billion yuan in 2016, with an average growth rate of 11.6% in 2013-2016, and is expected to grow to 2.55 billion yuan in 2017 2013-2017e Parkinson's drug market size (RMB 100 million) data source: Zhongkang CMH is used to treat Parkinson's disease drugs Influenced by the principle of preferred drug use, Dr agonists are dominant, with the largest market share of 92.0% in 2016 (principle of preferred drug: Patients younger than 65 years old and not accompanied by mental retardation can choose: ① non ergot dopamine receptor (DR) agonist; ② MAO-B inhibitor; ③ amantadine, if tremor is obvious and other anti PD drugs are not effective, anticholinergic drugs can be selected; ④ compound levodopa + catechol-O-methyltransferase (COMT) inhibitor; ⑤ compound levodopa; ④ and ⑤ generally in ①, ②, ③ schemes Add when the treatment effect is not good However, if the motor symptoms are improved significantly due to work needs, or cognitive impairment occurs, the ④ or ⑤ scheme can be selected first, or the ①, ② or ③ scheme can be applied in a small dose, and the ⑤ scheme can be used in a small dose Patients over 65 years old or accompanied with mental decline: Compound levodopa is the first choice If necessary, Dr agonist, MAO-B or COMT inhibitor can be added.) Data source of market share of anti Parkinson's disease drugs in 2016: according to the data of Zhongkang CMH and Zhongkang CMH, urban grade hospitals are still the main market, accounting for half of the market Retail pharmacies are the second largest market for Parkinson's disease drugs, accounting for more than 30% of the market share Although the market position of urban grass-roots and rural grass-roots is not high, the market scale has grown rapidly in the past two years, especially the market scale growth rate of urban grass-roots and rural grass-roots reaches 101.4% and 79.4% respectively, and the market share continues to rise Thanks to the implementation of hierarchical diagnosis and treatment and the overall development of the future medical market, the market position of grass-roots hospitals will be further improved Data source of five terminal antiparkinsonian drugs from 2013 to 2016: Zhongkang CMH market growth rate change of five terminal antiparkinsonian drugs from 2015 to 2016 Data source: according to Zhongkang CMH monitoring, Zhongkang CMH has a high market concentration of Parkinson's disease drugs, and the market share of dopahydrazine tablet, which leads the top seed in the market, is more than 40% in 2013-2016 Pramipexole hydrochloride tablets ranked the second with a growing trend, increasing to 22.6% in 2016 However, bromocriptine mesylate, which ranked third, declined Top 3 products lead the whole market, accounting for 78.2% of the total market share Market share data source of top 10 products of Parkinson's drugs: Zhongkang CMH It is worth mentioning that on March 22 this year, the FDA approved xadago (safinamide), a selective inhibitor of MAO-B jointly developed by Zambon and newron pharmaceutical company of Italy, as a Parkinson's disease treatment drug, which is the first new drug approved for Parkinson's disease treatment in the United States in more than a decade It is expected that more new Parkinson's disease drugs will be approved in the future.